Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in ...

--Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concept has been achieved in the Phase 2 ...

"We are pleased to advance our clinical development program for BIO89-100 with the initiation of this proof of concept trial following closely on our positive Phase 1a data announced in May," said ...

Sensorion will provide further updates of its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 CIO during the World Congress of Audiology, being held on September 19-22, 2024, in Paris ...

Investor Webcast Information Agios will host an investor webcast today at 7:30 a.m. ET to review the mitapivat proof-of-concept data in sickle cell disease and Phase 2 thalassemia data presented ...

IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors Published Sep 11, 2023 6:00am EDT ...

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 1b study, which ...

Ark Biosciences Reports Successful Completion of Phase II Proof-of-Concept Clinical Trial of Ziresovir for Treatment of Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection ...

EMERYVILLE, Calif., Oct. 18, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) announced today that its development partner, Alcon Research, Ltd., has concluded its "proof of ...

Phase 2a Design The open-label, proof-of-concept, Phase 2a portion of the study was designed to evaluate the safety and efficacy of AG-946 in adults with anemia due to lower-risk MDS.